Hutchison Medicine Sofantinib is approved for the treatment of advanced pancreatic neuroendocrine tumors

Hutchison Medicine recently announced that surufatinib was officially approved by the National Medical Products Administration (NMPA) of China for the treatment of advanced pancreatic neuroendocrine tumors (pNETs)

This approval is based on the results of a Chinese phase 3 clinical trial SANET-p (clinicaltrials.

The results showed that compared with the placebo group, the risk of disease progression or death of pNET patients in the sofatinib treatment group was significantly reduced by 51%

SANET-p study primary endpoint results

On December 30, 2020, Sofatinib was approved by the National Food and Drug Administration for the treatment of non-pancreatic neuroendocrine tumors

The results showed that compared with the placebo group, the risk of disease progression or death in the sofatinib treatment group was significantly reduced by 67%

SANET-ep study primary endpoint results

In China, it is estimated that there will be approximately 71,300 newly diagnosed neuroendocrine tumors in 2020

Neuroendocrine tumors (NET) originate from cells that interact with the nervous system or glands that produce hormones

Surufatinib is a new type of oral tyrosine kinase inhibitor with dual activities of anti-angiogenesis and immunomodulation

Reference source: Hutchison Medicine

Original title: Domestic kinase inhibitor! Hutchison Sofantinib (Sutaida®) was approved by the State Food and Drug Administration for a new indication: treatment of advanced pancreatic neuroendocrine tumors!